Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction

N Engl J Med. 2002 Jun 27;346(26):2047-52. doi: 10.1056/NEJMoa013456.

Abstract

Background: Among patients with suspected acute coronary syndromes, cardiac troponin T levels have prognostic value. However, there is concern that renal dysfunction may impair the prognostic value, because cardiac troponin T may be cleared by the kidney.

Methods: We analyzed the outcomes in 7033 patients enrolled in the Global Use of Strategies to Open Occluded Coronary Arteries IV trial who had complete base-line data on troponin T levels and creatinine clearance rates. The troponin T level was considered abnormal if it was 0.1 ng per milliliter or higher, and creatinine clearance was assessed in quartiles. The primary end point was a composite of death or myocardial infarction within 30 days.

Results: Death or myocardial infarction occurred in 581 patients. Among patients with a creatinine clearance above the 25th percentile value of 58.4 ml per minute, an abnormally elevated troponin T level was predictive of an increased risk of myocardial infarction or death (7 percent vs. 5 percent; adjusted odds ratio, 1.7; 95 percent confidence interval, 1.3 to 2.2; P<0.001). Among patients with a creatinine clearance in the lowest quartile, an elevated troponin T level was similarly predictive of increased risk (20 percent vs. 9 percent; adjusted odds ratio, 2.5; 95 percent confidence interval, 1.8 to 3.3; P<0.001). When the creatinine clearance rate was considered as a continuous variable and age, sex, ST-segment depression, heart failure, previous revascularization, diabetes mellitus, and other confounders had been accounted for, elevation of the troponin T level was independently predictive of risk across the entire spectrum of renal function.

Conclusions: Cardiac troponin T levels predict short-term prognosis in patients with acute coronary syndromes regardless of their level of creatinine clearance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abciximab
  • Aged
  • Angina Pectoris / complications
  • Angina Pectoris / drug therapy
  • Angina Pectoris / metabolism
  • Antibodies, Monoclonal / therapeutic use
  • Aspirin / therapeutic use
  • Biomarkers
  • Creatinine / metabolism
  • Female
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use
  • Logistic Models
  • Male
  • Middle Aged
  • Myocardial Infarction / complications
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / metabolism
  • Myocardial Ischemia / complications*
  • Myocardial Ischemia / drug therapy
  • Myocardial Ischemia / metabolism*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Renal Insufficiency / complications*
  • Renal Insufficiency / metabolism*
  • Survival Analysis
  • Troponin T / metabolism*

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Troponin T
  • Creatinine
  • Aspirin
  • Abciximab